{"filing":{"accession_number":"0001517022-26-000075","cik":"0001517022","ticker":"AKBA","company_name":"Akebia Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-21","primary_document":"akba-20261021.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702226000075/akba-20261021.htm"},"events":[{"id":37592,"run_id":34643,"accession_number":"0001517022-26-000075","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Akebia received a deficiency notice from Nasdaq on October 21, 2026, for failing to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until April 19, 2027) to regain compliance, with potential delisting if it fails to do so. This is a classic delisting-risk disclosure under Item 3.01, materially threatening the company's continued listing status.","company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42354,"accession_number":"0001517022-26-000075","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Akebia received a deficiency notice from Nasdaq on October 21, 2026, for failing to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until April 19, 2027) to regain compliance, with potential delisting if it fails to do so. This is a classic delisting-risk disclosure under Item 3.01, materially threatening the company's continued listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T20:10:04.621599+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42354,"accession_number":"0001517022-26-000075","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Akebia received a deficiency notice from Nasdaq on October 21, 2026, for failing to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until April 19, 2027) to regain compliance, with potential delisting if it fails to do so. This is a classic delisting-risk disclosure under Item 3.01, materially threatening the company's continued listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T20:10:04.621599+00:00","company_name":"Akebia Therapeutics, Inc.","ticker":"AKBA","filing_date":"2026-10-23"}]}